FindTrial
Sign In

Adalimub treatment to prevent recurrency post-surgery in Crohn disease.

Multicentric, randomized double blind clinical trial and paralell groups to compare Adalimub vs Azatioprina efficacy prevention in Crhon disease post-surgical recurrency after 52 weeks of treatment - APPRECIA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-000885-36-ES
Enrollment
Unknown
Registered
2011-11-29
Start date
2011-12-26
Completion date
Unknown
Last updated
2015-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compare efficay of Adalimub vs Azatioprina to prevent surgical intervention in Chron disease

Interventions

Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: Adalimumab CAS Number: 331731-18-1 Current Sponsor code: NA Other descriptive name: Adalimumab

Sponsors

GETECCU
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 84 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Spain

Contacts

Public ContactDr. Fernando Gomollón

GETECCU

info@congresosxxi.com+34944278855

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026